NEVVI Medicare utilization intelligence
or

← back

Provider profile

LAMBA, GURPREET M.B.B.S.

Hematology-Oncology · NPI 1427294271 · BURLINGTON, VT

1
Groups
52
Codes · 2024
207,401
Disclosed services

LAMBA, GURPREET is a Hematology-Oncology in BURLINGTON, VT, a member of 1 medical group, who billed 52 distinct codes to Medicare Part B in 2024.

Groups: REGIONAL CANCER CARE ASSOCIATES LLC (HACKENSACK, NJ)

Year: 2024 · 2023 · 2022 🔒 · 2021 🔒 · 2020 🔒

Provider overview · all codes · CY2024

207,401
disclosed services
52
codes billed to Medicare Part B
Prior year · CY2023 130,614 disclosed services

This provider's disclosed Medicare payments across all codes were in CY2024.

Dollars, place-of-service mix, business mix and national standing are part of the market analytics platform — built, not launched yet. Notify me at launch →

All figures are disclosed (CMS suppresses fewer-than-11-beneficiary rows) Medicare Part B fee-for-service — a subset, never complete totals; volumes are personal to this NPI, not attributed to any group. Standing is a billed-volume position among specialty peers with disclosed billing (national percentile; a provider's true standing can only be higher, never lower), not a statement about care. See Methods & Sources.

Procedures billed to Medicare Part B (2024)

Medicare Part B FFS · CY2024 · as published by CMS
This provider's Medicare volumes — services, beneficiary-episodes, and charges — are part of the market analytics platform — built, not launched yet. Notify me at launch →
CodeDescription Services Beneficiary-episodes Avg charge Avg Medicare payment
J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use)
J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj
J0185 Injection, aprepitant, 1 mg
J1627 Injection, granisetron, extended-release, 0.1 mg
J9271 Injection, pembrolizumab, 1 mg
J9267 Injection, paclitaxel, 1 mg
J1437 Injection, ferric derisomaltose, 10 mg
J1453 Injection, fosaprepitant, 1 mg
J0897 Injection, denosumab, 1 mg
J1100 Injection, dexamethasone sodium phosphate, 1 mg
J0885 Injection, epoetin alfa, (for non-esrd use), 1000 units
36415 Insertion of needle into vein for collection of blood sample
J2919 Injection, methylprednisolone sodium succinate, 5 mg
85025 Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count
J1568 Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg
J2405 Injection, ondansetron hydrochloride, per 1 mg
96367 Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less
99233 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes
J0640 Injection, leucovorin calcium, per 50 mg
99215 Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more
J9190 Injection, fluorouracil, 500 mg
99214 Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more
96372 Injection of drug or substance under skin or into muscle
G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's
J3490 Unclassified drugs
J1626 Injection, granisetron hydrochloride, 100 mcg
J1200 Injection, diphenhydramine hcl, up to 50 mg
99213 Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more
96413 Administration of chemotherapy into vein, 1 hour or less
96375 Injection of additional new drug or substance into vein
96365 Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less
J9045 Injection, carboplatin, 50 mg
99223 Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes
96361 Infusion into a vein for hydration, each additional hour
96401 Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle
J3489 Injection, zoledronic acid, 1 mg
J7030 Infusion, normal saline solution , 1000 cc
96366 Infusion into a vein for therapy, prevention, or diagnosis, each additional hour
J3420 Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg
96417 Administration of additional new drug or substance into vein, 1 hour or less
96523 Irrigation of implanted venous access drug delivery device
96360 Infusion into a vein for hydration, 31-60 minutes
96415 Administration of chemotherapy into vein, each additional hour
G0498 Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l
99232 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes
99205 New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more
99204 New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more
99442 Telephone medical discussion with physician, 11-20 minutes
96411 Administration of additional new drug or substance into vein using push technique
96368 Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion
99222 Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes
99443 Telephone medical discussion with physician, 21-30 minutes

These are this provider's own Medicare Part B fee-for-service volumes (CMS public data). CMS suppresses rows with fewer than 11 beneficiaries, so low-volume codes may be missing entirely — absence is not zero. Beneficiary-episodes count CMS's per-setting beneficiary figures, not unique patients. Average charge and average Medicare payment are weighted by service volume across office and facility settings. Volumes on this page are personal to the NPI and are not attributed to any physician group. See Methods & Sources.